Back in February, roughly 7 months ago, I recommended Unity to paying subscribers.This was a tough pick to make. In the weeks ahead, the market would have to deal with the onslaught of Liberation ...

Without analytics, it's impossible to achieve population health goals. Future problems within a health system can't be addressed without looking at data in the present and creating care models based ...

UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic ...

Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...